Browsing by Author "Akanksha Dubey"

Now showing 1 - 2 of 2

Emotion regulation difficulties in alexithymia and mental health
(PsychOpen, 2011) Rakesh Pandey; Prachi Saxena; Akanksha Dubey
Alexithymia, characterized by difficulty in identifying and describing feelings and a deficit in the cognitive modulation of emotions, has been linked with health related problems. Indirect empirical evidences suggest the possibility that alexithymia may potentially also relate with emotion regulation difficulties. However, the exact nature of the relationship between the two constructs has not been fully explored. The relationship between the two constructs may reflect the overlap of the content domains or dependence of one (e.g., emotion regulation difficulties) on the other (e.g., alexithymia). Given the link between the two constructs, it is also likely that alexithymics' health related difficulties may result from their impaired ability to regulate emotions. The present study tested the above theoretical propositions on 27 alexithymic and 26 non-alexithymic participants who were assessed on self-report measures of emotion regulation difficulties and general mental health. The findings revealed that compared to non-alexithymics, the alexithymics showed greater emotion regulation difficulties and such affective difficulties differentiated the two groups with a very high accuracy. Further, the observation of two orthogonal components (emotion regulation difficulties and alexithymia) with a minimum overlap suggests that these constructs represent two independent domains of behavior. Findings also revealed that alexithymics reported more health related problems as compared to non-alexithymics and the health problems of alexithymics are likely to be an outcome of their emotion regulation difficulties (indicated by a non-significant health difference after controlling for emotion regulation difficulties). The findings imply that alexithymia is associated with emotion regulation difficulties and such difficulties largely contribute to health related problems.
Heteroaryl-Capped Hydroxamic Acid Derivatives with Varied Linkers: Synthesis and Anticancer Evaluation with Various Apoptosis Analyses in Breast Cancer Cells, Including Docking, Simulation, DFT, and ADMET Studies
(Multidisciplinary Digital Publishing Institute (MDPI), 2025) Ekta Shirbhate; Biplob Koch; Vaibhav Singh; Akanksha Dubey; Haya Khader Ahmad Yasin; H. Rajak
Background/Objectives: Cancer suffers from unresolved therapeutic challenges owing to the lack of targeted therapies and heightened recurrence risk. This study aimed to investigate the new series of hydroxamate by structurally modifying the pharmacophore of vorinostat. Methods: The present work involves the synthesis of 15 differently substituted 2H-1,2,3-triazole-based hydroxamide analogs by employing triazole ring as a cap with varied linker fragments. The compounds were evaluated for their anticancer effect, especially their anti-breast cancer response. Molecular docking and molecular dynamics simulations were conducted to examine binding interactions. Results: Results indicated that among all synthesized hybrids, the molecule VI(i) inhibits the growth of MCF-7 and A-549 cells (GI50 < 10 μg/mL) in an antiproliferative assay. Compound VI(i) was also tested for cytotoxic activity by employing an MTT assay against A549, MCF-7, and MDA-MB-231 cell lines, and the findings indicate its potent anticancer response, especially against MCF-7 cells with IC50 of 60 µg/mL. However, it experiences minimal toxicity towards the normal cell line (HEK-293). Mechanistic studies revealed a dual-pathway activation: first, apoptosis (17.18% of early and 10.22% of late apoptotic cells by annexin V/PI analysis); second, cell cycle arrest at the S and G2/M phases. It also promotes ROS generation in a concentration-dependent manner. The HDAC–inhibitory assay, extended in silico molecular docking, and MD simulation experiments further validated its significant binding affinity towards HDAC 1 and 6 isoforms. DFT and ADMET screening further support the biological proclivity of the title compounds. The notable biological contribution of VI(i) highlights it as a potential candidate, especially against breast cancer cells. © 2025 by the authors.